Search

Biogen Idec said Friday that it has launched an effort to acquire Redwood City-based Facet Biotech, in a deal worth $14.50 per share in cash for Facet. According to Biogen Idec, the offer is approximately 64% over the September 3rd closing pricing of Facet. In a letter relased by Biogen, it said it was "deeply disappointed" in a collaboration with Trubion announced by Facet, plus a rejection by Facet on August 25th to discuss a possible buyout offer.
posted on Friday, September 4, 2009

Related companies:
Biogen IDEC

Related stories:
> Facet Biotech Acquired By Abbott
> Clarus Ventures Names Venture Partner
> True North Therapeutics Gets $22M
> Vir Biotechnology Raises More Than $150M To Fight Infectious Disease
> blinkx Drops MIVA Bid

---

silicontap.com Home